Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920742 | 1.00 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL7743342 | 0.90 | AOC3 (0.55) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL13850026 | 0.86 | AOC3 (0.62) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL15195819 | 0.86 | AOC3 (0.62) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL3907003 | 0.86 | AOC3 (0.62) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL7784227 | 0.85 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL7102577 | 0.85 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL16419134 | 0.85 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL22785842 | 0.85 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL6492140 | 0.85 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115385782-A | Mechanochemical synthesis method of benzoyl compound | 兰州大学 | 2022-11-25 | — | — | CN | disclosed |
| US-20220127215-A1 | A COPPER-CATALYZED METHOD AND APPLICATION FOR PREPARING ALDEHYDES OR KETONES BY OXIDIZING ALCOHOLS WITH OXYGEN AS AN OXIDANT | FUDAN UNIVERSITY (CN) | 2022-04-28 | — | — | US | disclosed |
| EP-3919469-A1 | COPPER-CATALYZED METHOD FOR PREPARING ALDEHYDE OR KETONE COMPOUND BY OXIDIZING ALCOHOL BY USING OXYGEN AS OXIDANT, AND APPLICATION THEREOF | Fudan University (CN) | 2021-12-08 | — | — | EP | disclosed |
| EP-3906969-A1 | ANTIHYPERTENSIVE POLYOL COMPOUND AND DERIVATIVE THEREOF | East China University of Science and Technology (CN) | 2021-11-10 | — | — | EP | disclosed |
| WO-2020156238-A1 | COPPER-CATALYZED METHOD FOR PREPARING ALDEHYDE OR KETONE COMPOUND BY OXIDIZING ALCOHOL BY USING OXYGEN AS OXIDANT, AND APPLICATION THEREOF | 复旦大学 | 2020-08-06 | — | — | WO | disclosed |
| EP-3307739-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016202253-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| US-8309715-B2 | Camphor-derived β-amino alcohol compounds, method for manufacturing the same and asymmetric addition of organozinc to aldehydes using the same | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-11-13 | — | — | US | disclosed |
| US-20120071432-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071432-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2012-03-22 | — | — | US | disclosed |
| EP-1505156-A1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | Consortium für elektrochemische Industrie GmbH (DE) | 2005-02-09 | — | — | EP | disclosed |
| EP-1300381-A1 | Process for preparing optically active alcohols | Japan Science and Technology Corporation (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6365398-B1 | REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| US-6184381-B1 | USEFUL AS INTERMEDIATES FOR SYNTHESIZING PHARMACEUTICAL CHEMICALS, LIQUID CRYSTAL MATERIALS AND AGENTS FOR OPTICAL RESOLUTION, REDUCTION, KETONES TO ALCOHOL, IMINES TO AMINES | JAPAN SCIENCE & TECHNOLOGY CORP. (JP) | 2001-02-06 | — | — | US | disclosed |
| CN-1266904-A | Process for preparing stereoisomer carboxylate | BASF AG (DE) | 2000-09-20 | — | — | CN | disclosed |
| EP-1031629-A2 | Method of preparation of stereoisomeric carboxylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-30 | — | — | EP | disclosed |
| EP-0916637-A1 | PROCESS FOR PREPARATING OPTICALLY ACTIVE COMPOUNDS | Japan Science and Technology Corporation (JP) | 1999-05-19 | — | — | EP | disclosed |
| CN-1117291-A | 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections | UPJOHN CO (US) | 1996-02-21 | — | — | CN | disclosed |
| EP-0271287-A2 | Quinoline dioic acids and amides | MERCK FROSST CANADA INC. (CA) | 1988-06-15 | — | — | EP | disclosed |
| US-4094994-A | ANTICANCER AGENTS, TUMOR INHIBITION, HORMONE-DEPENDENT CARCINOMAS | KLINGE PHARMA GMBH (DT) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127215-A1 | A COPPER-CATALYZED METHOD AND APPLICATION FOR PREPARING ALDEHYDES OR KETONES BY OXIDIZING ALCOHOLS WITH OXYGEN AS AN OXIDANT | SOD1, ALDH2, AOC2 | AOC3 6/4885L3MBTL1 2054/4885CHRM2 1265/4885 |
| US-20120071432-A1 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS | PMP22, INA, SMN1; SMN2 | AOC3 2368/4885L3MBTL1 504/4885CHRM2 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.